Preparation for International Cooperation on Cosmetics Regulation Fourteenth Annual Meeting; Public Meeting, 12569 [2020-04318]
Download as PDF
Federal Register / Vol. 85, No. 42 / Tuesday, March 3, 2020 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2020–N–0001]
Preparation for International
Cooperation on Cosmetics Regulation
Fourteenth Annual Meeting; Public
Meeting
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice of public meeting.
The Food and Drug
Administration (FDA or we) is
announcing the following public
meeting entitled ‘‘International
Cooperation on Cosmetics Regulation
(ICCR)—Preparation for ICCR–14
Meeting.’’ The purpose of the public
meeting is to invite public input on
various topics pertaining to the
regulation of cosmetics. We may use
this input to help us prepare for the
ICCR–14 meeting that will be held June
8 to 10, 2020, in Brussels, Belgium.
DATES: The public meeting will be held
on April 14, 2020, from 2 p.m. to 4 p.m.
See the SUPPLEMENTARY INFORMATION
section for registration date and
information.
ADDRESSES: The public meeting will be
held at the Food and Drug
Administration, Center for Food Safety
and Applied Nutrition, 5001 Campus
Dr., Wiley Auditorium (first floor),
College Park, MD 20740. Entrance for
the public meeting participants is
through the Harvey W. Wiley Federal
Building, where routine security check
procedures will be performed.
FOR FURTHER INFORMATION CONTACT:
Deborah Smegal, Office of Cosmetics
and Colors, Food and Drug
Administration, 5001 Campus Dr. (HFS–
100), College Park, MD 20740, 240–402–
1818, Deborah.Smegal@fda.hhs.gov.
SUPPLEMENTARY INFORMATION:
lotter on DSKBCFDHB2PROD with NOTICES
SUMMARY:
I. Background
The intention of the ICCR multilateral
framework is to pave the way for the
removal of regulatory obstacles to
international trade while maintaining
global consumer protection. The
purpose of this meeting is to invite
public input on various topics
pertaining to the regulation of
cosmetics. We may use this input to
help us prepare for the ICCR–14 meeting
that will be held June 8 to 10, 2020, in
Brussels, Belgium.
ICCR is a voluntary international
group of cosmetics regulatory
authorities from Brazil, Canada, the
European Union, Japan, and the United
VerDate Sep<11>2014
17:19 Mar 02, 2020
Jkt 250001
States of America. These regulatory
authority members will engage in
constructive dialogue with their
relevant cosmetics industry trade
associations and public advocacy
groups. Currently, the ICCR members
are: The Brazilian Health Surveillance
Agency; Health Canada; the European
Commission Directorate General for
Internal Market, Industry,
Entrepreneurship, and Small and
Medium-sized Enterprises; the Ministry
of Health, Labor, and Welfare of Japan;
and United States Food and Drug
Administration. All decisions are made
by consensus and will be compatible
with the laws, policies, rules,
regulations, and directives of the
respective administrations and
governments. Members will implement
and/or promote actions or documents
within their own jurisdictions and seek
convergence of regulatory policies and
practices. Successful implementation
will need input from stakeholders.
II. Topics for Discussion at the Public
Meeting
We will make the agenda for the
public meeting available by April 7,
2020, on the internet at https://
www.fda.gov/Cosmetics/
InternationalActivities/ICCR/
default.htm.
III. Participating in the Public Meeting
Registration: To register for the public
meeting, send registration information
(including your name, title, affiliation,
address, email, and telephone) to
Deborah Smegal (see FOR FURTHER
INFORMATION CONTACT) by March 31,
2020. If you would like to listen to the
meeting by phone, please submit a
request for a dial-in number by March
31, 2020 (see FOR FURTHER INFORMATION
CONTACT). If you need special
accommodations due to a disability,
please contact Deborah Smegal by April
7, 2020.
Requests for Oral Presentations: If you
wish to present, you should notify
Deborah Smegal by March 31, 2020, and
submit a brief statement of the general
nature of the presentation: What you
wish to present, your name, title,
affiliation, address, email, and
telephone, and indicate the approximate
amount of time needed to make your
presentation. You may wish to present
proposals for future ICCR agenda items,
data, information, or views, in person or
in writing, on issues pending at the
public meeting or a topic related to a
previous meeting. There will be no
presentations by phone. Time allotted
for oral presentations may be limited to
10 minutes or less for each presenter,
PO 00000
Frm 00076
Fmt 4703
Sfmt 4703
12569
depending on the number of requests
received.
Transcripts: Please be advised that as
soon as a transcript of the public
meeting is available, it will be accessible
at https://www.regulations.gov. It may
also be viewed at the Dockets
Management Staff (HFA–305), Food and
Drug Administration, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20850.
Dated: February 26, 2020.
Lowell J. Schiller,
Principal Associate Commissioner for Policy.
[FR Doc. 2020–04318 Filed 3–2–20; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of a
meeting of the National Cancer Institute
Council of Research Advocates.
The meeting will be open to the
public, with attendance limited to space
available. Individuals who plan to
attend and need special assistance, such
as sign language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting. The open
session will be videocast and can be
accessed from the NIH Videocasting and
Podcasting website (https://
videocast.nih.gov).
Name of Committee: National Cancer
Institute Council of Research Advocates.
Date: May 11, 2020.
Time: 9:30 a.m. to 4:00 p.m.
Agenda: Welcome and Chairman’s
Remarks, NCI Updates, Legislative Update,
and Director’s Update.
Place: National Institutes of Health, 40
Convent Drive, Building 40, Room 1201/1203
Bethesda, MD 20892.
Contact Person: Amy Williams, NCI Office
of Advocacy Relations, National Cancer
Institute, NIH, 31 Center Drive, Building 31,
Room 10A28, Bethesda, MD 20892, 240–781–
3360, williaam@mail.nih.gov.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
In the interest of security, NIH has
instituted stringent procedures for entrance
onto the NIH campus. All visitor vehicles,
including taxicabs, hotel, and airport shuttles
will be inspected before being allowed on
campus. Visitors will be asked to show one
form of identification (for example, a
E:\FR\FM\03MRN1.SGM
03MRN1
Agencies
[Federal Register Volume 85, Number 42 (Tuesday, March 3, 2020)]
[Notices]
[Page 12569]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-04318]
[[Page 12569]]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2020-N-0001]
Preparation for International Cooperation on Cosmetics Regulation
Fourteenth Annual Meeting; Public Meeting
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice of public meeting.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA or we) is announcing the
following public meeting entitled ``International Cooperation on
Cosmetics Regulation (ICCR)--Preparation for ICCR-14 Meeting.'' The
purpose of the public meeting is to invite public input on various
topics pertaining to the regulation of cosmetics. We may use this input
to help us prepare for the ICCR-14 meeting that will be held June 8 to
10, 2020, in Brussels, Belgium.
DATES: The public meeting will be held on April 14, 2020, from 2 p.m.
to 4 p.m. See the SUPPLEMENTARY INFORMATION section for registration
date and information.
ADDRESSES: The public meeting will be held at the Food and Drug
Administration, Center for Food Safety and Applied Nutrition, 5001
Campus Dr., Wiley Auditorium (first floor), College Park, MD 20740.
Entrance for the public meeting participants is through the Harvey W.
Wiley Federal Building, where routine security check procedures will be
performed.
FOR FURTHER INFORMATION CONTACT: Deborah Smegal, Office of Cosmetics
and Colors, Food and Drug Administration, 5001 Campus Dr. (HFS-100),
College Park, MD 20740, 240-402-1818, [email protected].
SUPPLEMENTARY INFORMATION:
I. Background
The intention of the ICCR multilateral framework is to pave the way
for the removal of regulatory obstacles to international trade while
maintaining global consumer protection. The purpose of this meeting is
to invite public input on various topics pertaining to the regulation
of cosmetics. We may use this input to help us prepare for the ICCR-14
meeting that will be held June 8 to 10, 2020, in Brussels, Belgium.
ICCR is a voluntary international group of cosmetics regulatory
authorities from Brazil, Canada, the European Union, Japan, and the
United States of America. These regulatory authority members will
engage in constructive dialogue with their relevant cosmetics industry
trade associations and public advocacy groups. Currently, the ICCR
members are: The Brazilian Health Surveillance Agency; Health Canada;
the European Commission Directorate General for Internal Market,
Industry, Entrepreneurship, and Small and Medium-sized Enterprises; the
Ministry of Health, Labor, and Welfare of Japan; and United States Food
and Drug Administration. All decisions are made by consensus and will
be compatible with the laws, policies, rules, regulations, and
directives of the respective administrations and governments. Members
will implement and/or promote actions or documents within their own
jurisdictions and seek convergence of regulatory policies and
practices. Successful implementation will need input from stakeholders.
II. Topics for Discussion at the Public Meeting
We will make the agenda for the public meeting available by April
7, 2020, on the internet at https://www.fda.gov/Cosmetics/InternationalActivities/ICCR/default.htm.
III. Participating in the Public Meeting
Registration: To register for the public meeting, send registration
information (including your name, title, affiliation, address, email,
and telephone) to Deborah Smegal (see FOR FURTHER INFORMATION CONTACT)
by March 31, 2020. If you would like to listen to the meeting by phone,
please submit a request for a dial-in number by March 31, 2020 (see FOR
FURTHER INFORMATION CONTACT). If you need special accommodations due to
a disability, please contact Deborah Smegal by April 7, 2020.
Requests for Oral Presentations: If you wish to present, you should
notify Deborah Smegal by March 31, 2020, and submit a brief statement
of the general nature of the presentation: What you wish to present,
your name, title, affiliation, address, email, and telephone, and
indicate the approximate amount of time needed to make your
presentation. You may wish to present proposals for future ICCR agenda
items, data, information, or views, in person or in writing, on issues
pending at the public meeting or a topic related to a previous meeting.
There will be no presentations by phone. Time allotted for oral
presentations may be limited to 10 minutes or less for each presenter,
depending on the number of requests received.
Transcripts: Please be advised that as soon as a transcript of the
public meeting is available, it will be accessible at https://www.regulations.gov. It may also be viewed at the Dockets Management
Staff (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm.
1061, Rockville, MD 20850.
Dated: February 26, 2020.
Lowell J. Schiller,
Principal Associate Commissioner for Policy.
[FR Doc. 2020-04318 Filed 3-2-20; 8:45 am]
BILLING CODE 4164-01-P